XTNT
AMEXXtant Medical Holdings Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Website
News25/Ratings1
News · 26 weeks34+100%
2025-10-262026-04-19
Mix1290d
- Other5(42%)
- SEC Filings4(33%)
- Earnings2(17%)
- Insider1(8%)
Latest news
25 items- SECXtant Medical Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Xtant Medical Holdings, Inc. (0001453593) (Filer)
- PRXtant Medical and Dilon Technologies Announce Exclusive U.S. Distribution Agreement for Dilon's HEMOBLAST® Bellows ProductXtant has hired Dilon's U.S. sales team to assist in selling the HEMOBLAST® Bellows product and penetrating the estimated $2.0 billion global addressable market for hemostatic products BELGRADE, Mont. and NEWPORT NEWS, Va., April 13, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, and Dilon Technologies, Inc., a medical device manufacturer, today announced that the companies have entered into an agreement whereby Xtant has acquired exclusive U.S. distribution rights to Dilon's HEMOBLAST® Bellows for high-performance hemostasis following certain surgical procedures.
- PRXtant Medical and Montana Governor's Office of Community Service Announce Support for "Threshold of Life" MemorialBELGRADE, Mont., April 9, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), in partnership with the Montana Governor's Office of Community Service (GOCS), today announced support for the Threshold of Life Memorial, a statewide initiative honoring organ, eye, and tissue donors and the lives they have impacted. Planned for installation on the Montana State Capitol grounds in Helena, the outdoor memorial will serve as a lasting tribute to donors, both living and deceased. It will be a place of reflection for families, recipients, and those awaiting transplantation. The
- SECSEC Form 10-K filed by Xtant Medical Holdings Inc.10-K - Xtant Medical Holdings, Inc. (0001453593) (Filer)
- SECXtant Medical Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Xtant Medical Holdings, Inc. (0001453593) (Filer)
- PRXtant Medical Reports Fourth Quarter and Full-Year 2025 Financial ResultsFull year 2025 revenue totals $133.9 million, an increase of 14% year-over-yearXtant delivers positive net income, adjusted EBITDA and operating cash flowTotal cash of $17.3 million as of December 31, 2025 with an additional $10.5 million received subsequent to year end related to divestitureBELGRADE, Mont., March 31, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today reported financial and operating results for the fourth quarter and full-year ended December 31, 2025.
- PRXtant Medical to Announce Fourth Quarter and Full Year 2025 Financial Results on March 31, 2026BELGRADE, Mont., March 25, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2025, before the start of trading on Tuesday, March 31, 2026. Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call at 8:30 AM ET on that day. Conference Details:Conference Date: Tuesday, March 31, 2026Confere
- SECSEC Form 8-K filed by Xtant Medical Holdings Inc.8-K - Xtant Medical Holdings, Inc. (0001453593) (Filer)
- PRXtant Medical Finalizes Companion Spine TransactionsXtant received $10.7 million in satisfaction of unsecured promissory note issued to Xtant by Companion Spine plus related working capital adjustments BELGRADE, Mont., March 2, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced that it has received $10.7 million from Companion Spine related to Companion Spine's purchase of Xtant's Coflex® assets and Paradigm OUS businesses in December 2025, bringing the total aggregate purchase price for the two divestitures to $21.4 million. With this payment, the transactions have now been finalized.
- PRXtant Medical to Participate in the Canaccord Genuity 2026 Musculoskeletal ConferenceBELGRADE, Mont., Feb. 25, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and wound care disorders, today announced that Sean Browne, CEO, Scott Neils, CFO, and Mark Schallenberger, COO, will be participating in the Canaccord Genuity 2026 Musculoskeletal Conference, which is being held March 2, 2026, in New Orleans and virtually. A webcast of the company's presentation will be available here as of Monday, February 2nd at 2:00 P.M. (ET). In addition, Xtant's m
- INSIDERChief Operating Officer Schallenberger Mark A. covered exercise/tax liability with 7,709 shares, decreasing direct ownership by 1% to 663,157 units (SEC Form 4)4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Xtant Medical Holdings Inc.SCHEDULE 13G/A - Xtant Medical Holdings, Inc. (0001453593) (Subject)
- INSIDERCFO and Assistant Secretary Neils Scott C covered exercise/tax liability with 8,084 shares, decreasing direct ownership by 0.95% to 843,381 units (SEC Form 4)4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)
- SECSEC Form 8-K filed by Xtant Medical Holdings Inc.8-K - Xtant Medical Holdings, Inc. (0001453593) (Filer)
- PRXtant Medical Announces Commercial Launch of its Next-Generation nanOss Strata™ Synthetic Bone GraftnanOss Strata™ is designed to more closely mimic the structure of human bone, increase the graft's surface area, improve osteoconductivity and enhance the stimulation of cellular activity BELGRADE, Mont., Dec. 11, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced the commercial launch of its next-generation innovative synthetic bone graft in the nanOss line, Strata™. nanOss Strata is manufactured from hydroxycarbonapatite (HCA), a material with hi
- SECXtant Medical Holdings Inc. filed SEC Form 8-K: Events That Accelerate or Increase a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Xtant Medical Holdings, Inc. (0001453593) (Filer)
- PRCompanion Spine LLC Completes Acquisition of the Business and Assets of Paradigm Spine GmbH, including the Coflex® and CoFix® Spine Implants and All Other Implant Systems, from Xtant™ Medical Holdings, Inc.Companion Spine is the first company in the world with a product portfolio solely focused on Total Disease State Solutions™ ("TDS™") for degenerative spine diseases. This acquisition creates the world's largest and most comprehensive product portfolio of minimally invasive surgical ("MIS") Posterior Dynamic Solutions™ of spine stabilization and motion preserving implants. The combined company can now treat the full range of lumbar spinal stenosis ("LSS") and degenerative disc disease ("DDD") conditions across the spectrum of disease progression with our SMART™ (Solution Based, Minimal Access, Reliable Technologies) portfolio. Companion Spine LLC ("Companion Spine" or "the Company")
- PRXtant Medical Completes Sale of its Coflex® Assets and Paradigm OUS Businesses to Companion SpineBELGRADE, Mont., Dec. 1, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced that the company has completed its previously announced sale of certain non-core Coflex® spinal implant assets and all OUS entities of Paradigm Spine GmbH to Companion Spine, LLC, and its affiliates. The purchase price of the transaction was approximately $19.2 million, consisting of $11.0 million in cash and $8.2 million in short-term seller financing in the form of
- INSIDERAmendment: Director Bakewell John K was granted 158,228 shares, increasing direct ownership by 21% to 914,116 units (SEC Form 4)4/A - Xtant Medical Holdings, Inc. (0001453593) (Issuer)
- INSIDERDirector Vizirgianakis Stavros G. was granted 553,797 shares, increasing direct ownership by 8% to 7,515,570 units (SEC Form 4)4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)
- INSIDERDirector Beeson Jonn R. was granted 158,228 shares, increasing direct ownership by 44% to 517,619 units (SEC Form 4)4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)
- INSIDERDirector Bakewell John K was granted 158,228 shares (SEC Form 4)4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)
- INSIDERDirector Jain Abhinav was granted 158,228 shares (SEC Form 4)4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)
- INSIDERDirector Lipschultz Tyler was granted 158,228 shares (SEC Form 4)4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)
- INSIDERPresident and CEO Browne Sean E was granted 394,937 shares, increasing direct ownership by 18% to 2,575,274 units (SEC Form 4)4 - Xtant Medical Holdings, Inc. (0001453593) (Issuer)